Shares in Solid Biosciences Inc. plunged 71 percent after a clinical trial testing the company’s gene therapy for a muscle-wasting disorder was halted for the second time in less than two years.
U.S. drugmaker Bristol-Myers Squibb Co. reported higher-than-expected third-quarter 2019 profit, helped by strong sales of the blood thinner Eliquis, even as growth of the company’s blockbuster cancer treatment Opdivo slowed.
Baxter International Inc. was named in a complaint for improperly marketing opioid drugs and revealed an internal probe into the medical supplier’s accounting, sending the company’s shares down.
Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.
The U.S. FDA approved a bone-building drug from Pfenex Inc. to treat osteoporosis in certain patients at high risk for fractures, marking the company’s first commercial product.
AstraZeneca presented results for a late-stage clinical trial of Lynparza against prostate cancer, which the company hopes could lead to wider regulatory approval for more forms of the disease.
Novartis said Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose the drug over Pfizer’s blockbuster Ibrance.
GlaxoSmithKline and AstraZeneca both reported late-stage clinical trial results that will likely make their competing medicines available to a wider group of ovarian cancer patients, possibly helping GSK catch the company’s rival in a highly contested drug class.
Danish drugmaker Novo Nordisk is aiming for a big slice of the multibillion-dollar diabetes market with a new pill approved by U.S. authorities that caters for patients with an aversion to needles.
Denmark’s Lundbeck agreed to buy Alder BioPharmaceuticals in a deal valued at almost $2 billion, hoping to reap profits from a potential blockbuster migraine drug.